Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5828933 | 0.85 | MEN1 (0.41) | ALDH1A1MEN1KMT2AABCB1L3MBTL1 | |
| SCHEMBL5829269 | 0.85 | MEN1 (0.41) | ALDH1A1MEN1KMT2AABCB1L3MBTL1 | |
| SCHEMBL31138116 | 0.84 | USP2 (0.47) | USP2SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL6697403 | 0.83 | MEN1 (0.44) | ALDH1A1MEN1KMT2AABCB1L3MBTL1 | |
| SCHEMBL31757749 | 0.81 | USP2 (0.52) | USP2SMN1; SMN2ALDH1A1ANPEPNPC1 | |
| SCHEMBL17871298 | 0.81 | USP2 (0.49) | USP2SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL27669297 | 0.75 | SMN1; SMN2 (0.51) | USP2SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL27669233 | 0.75 | SMN1; SMN2 (0.51) | USP2SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL8902413 | 0.74 | SMN1; SMN2 (0.55) | USP2SMN1; SMN2ALDH1A1KMT2ARECQL | |
| SCHEMBL357027 | 0.74 | CTSK (0.49) | USP2SMN1; SMN2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192153-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2009-07-30 | — | — | US | disclosed |
| EP-1939198-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192153-A1 | NOVEL ADENINE COMPOUND | ADORA1, SLC28A1, ADORA2A | USP2 4558/4885SMN1; SMN2 986/4885ALDH1A1 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.